Moody Aldrich Partners LLC decreased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 124,984 shares of the company’s stock after selling 12,528 shares during the period. Moody Aldrich Partners LLC owned about 0.07% […]

Related Keywords

Randalw Scott , Raymond James , Bio Pharma , Bridgebio Pharma , Hannah Valantine , Moody Aldrich Partners , Citigroup , Assetmark Inc , Nasdaq , Quantamental Technologies , Bridgebio Pharma Inc , Jpmorgan Chase Co , Analysts Bio Pharma Inc , Bio Pharma Inc , Free Report , Aldrich Partners , Street Markets , Investment Management , Get Free Report , Director Randal , Director Hannah Valantine , Bridgebio Pharma Daily ,